THOROFARE, N.J.,, July 18, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, announces another agreement with a major Independent Sales Representative (ISR) organization, adding sales and marketing coverage for the Company’s rapid test for heparin-induced thrombocytopenia (HIT) across an additional 12 states.

The agreement with Appleton Medical Services, based in St. Louis, Missouri, will place Akers Bio’s flagship HIT test into the hands of a further 14 speciality medical product sales representatives, focused on implementing solutions into the clinical pathway.

Appleton Medical Services will target clinical end-users of, and those able to prescribe, HIT tests, including surgeons and surgical teams. Their teams will provide sales and marketing exposure for PIFA Heparin/PF4 Rapid Assay products in Indiana, Kentucky, Minnesota, Illinois, Wisconsin, Mississippi, Louisiana, Missouri, Kansas, Iowa, Nebraska and Arkansas; as well as providing coverage in certain areas of Texas, Wyoming and Colorado which are not currently represented by existing ISR partners with coverage in those states.

Since the start of 2018, Akers Bio has developed sales and marketing coverage through ISRs in 39 of the 50 United States, covering more than 75 per cent of the country’s total population.

John J. Gormally, Chief Executive Officer of Akers Bio, commented: “A key goal for Akers Bio has been to establish broad Independent Sales Representative coverage for our primary commercialized test, leveraging the specialized skills and relevant relationships of our chosen partners in their respective regions. This is central to the strategy of raising awareness of the benefits of our rapid heparin platelet factor 4 antibody test and to influencing the clinical pathway for the diagnosis of HIT.

As a result of the tremendous efforts of our sales and marketing team, we are now represented by 55 sales people from 9 organizations covering 39 states which are home to over three-quarters of the US population. We fully expect to further expand this footprint as we focus on driving profitable growth for our core products.”

About Akers Biosciences, Inc.

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio.

Cautionary Note Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, compliance with the requirements of various regulatory agencies, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions, as they relate to the Company, its subsidiaries, or its management. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, performance, prospects, and opportunities to may differ materially from those set forth in, or implied by, the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

For more information:

Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Tel. +1 856 848 8698

Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7390 0234
Email: akers@vigocomms.com